CDC20, a potential cancer therapeutic target, is negatively regulated by p53
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“For instance, Trastuzumab, a recombinant humanized monoclonal antibody to the extracellular domain of HER2 provides substantial clinical benefits in patients with HER2overexpressing breast cancer (Slamon et al., 2001).”
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 2×
“The p53 protein is induced and activated at nucleus by a variety of genotoxic stresses such as DNA damage, hypoxia, oxidative stress and heat shock (Vogelstein et al., 2000).”
BackgroundRequirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803 · cited 1×
“…in the CDC20 promoter region were required for negative regulation of CDC20 by p21. p21 is known to participate in the G2/M checkpoint as well as at the G1 arrest (Bunz et al., 1998). p21 inhibits the activity of CDKs and subsequently blocks the phosphorylation of RB tumor suppressor protein.”
BackgroundRestoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · cited 1×
“Several small molecular compounds were developed to restore mutant p53 conformation to wild type or to disrupt MDM2-p53 binding and increase the stability of p53 (Bykov et al., 2002; Issaeva et al., 2004).”
BackgroundA ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage
Tanaka, H., Arakawa, H., Yamaguchi, T., Shiraishi, K., Fukuda, S., Matsui, K., Takei, Y., & Nakamura, Y. (2000) · Nature · doi:10.1038/35003506 · Cited by 904
Self-citationTarget gene specificity of E2F and pocket protein family members in living cells
Wells, J., Boyd, K. E., Fry, C. J., Bartley, S. M., & Farnham, P. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.16.5797-5807.2000 · Cited by 229 · cited 6×
“By addition of excess unlabeled DNA oligonucleotides corresponding to 55/ 29 of CDC20 (self, lanes 3–4) or E2F consensus sequence (E2F, lane5–6), the shift band was disappeared.”
BackgroundInfluentialp130/E2F4 Binds to and Represses the cdc2 Promoter in Response to p53
Taylor, W. R., Schönthal, A. H., Galante, J., & Stark, G. R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m005101200 · Cited by 110 · cited 5×
“p21 suppressed CDC20 expression It was previously reported that p21, a p53-inducible cellcycle regulator, repressed CDC2 expression through the CDE–CHR elements in CDC2 promoter (Taylor et al., 2001).”
BackgroundInfluential
Research works printed but not linked: 43
- Ashida S, Nakagawa H, Katagiri T, Furihata M, Iiizumi M, Anazawa Y et al. (2004). Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res 64: 5963–5972. · DOI · Paper page
- el-Deiry WS . (1998). Regulation of p53 downstream genes. Semin Cancer Biol 8: 345–357. · DOI · Paper page
- Fang G, Yu H, Kirschner MW . (1998). The checkpoint protein MAD2 and the mitotic regulator CDC20 form a ternary complex with the anaphase-promoting complex to control anaphase initiation. Genes Dev 12: 1871–1883. · DOI · Paper page
- Fung TK, Poon RY . (2005). A roller coaster ride with the mitotic cyclins. Semin Cell Dev Biol 16: 335–342. · DOI · Paper page
- Hasegawa S, Furukawa Y, Li M, Satoh S, Kato T, Watanabe T et al. (2002). Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23,040 genes. Cancer Res 62: 7012–7017.
- Hirota E, Yan L, Tsunoda T, Ashida S, Fujime M, Shuin T et al. (2006). Genome-wide gene expression profiles of clear cell renal cell carcinoma: identification of molecular targets for treatment of renal cell carcinoma. Int J Oncol 29: 799–827.
- Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M . (2002). Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277: 3247–3257. · DOI · Paper page
- Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T et al. (1994). Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22: 3551–3555.
- Innocente SA, Lee JM . (2005). p53 is a NF-Y- and p21-independent, Sp1-dependent repressor of cyclin B1 transcription. FEBS Lett 579: 1001–1007. · DOI · Paper page
- Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M et al. (2004). Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10: 1321–1328. · DOI · Paper page
- Jinawath N, Furukawa Y, Hasegawa S, Li M, Tsunoda T, Satoh S et al. (2004). Comparison of gene-expression profiles between diffuse- and intestinal-type gastric cancers using a genome-wide cDNA microarray. Oncogene 23: 6830–6844. · DOI
- Kaneta Y, Kagami Y, Katagiri T, Tsunoda T, Jin-nai I, Taguchi H et al. (2002). Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis. Jpn J Cancer Res 93: 849–856. · doi:10.1111/j.1349-7006.2002.tb01328.x
- Kikuchi T, Daigo Y, Katagiri T, Tsunoda T, Okada K, Kakiuchi S et al. (2003). Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 22: 2192–2205. · DOI · Paper page
- Kim JM, Sohn HY, Yoon SY, Oh JH, Yang JO, Kim JH et al. (2005). Identification of gastric cancer-related genes using a cDNA microarray containing novel expressed sequence tags expressed in gastric cancer cells. Clin Cancer Res 11: 473–482. · DOI · Paper page
- Kitahara O, Furukawa Y, Tanaka T, Kihara C, Ono K, Yanagawa R et al. (2001). Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia. Cancer Res 61: 3544–3549.
- Kitahara O, Katagiri T, Tsunoda T, Harima Y, Nakamura Y . (2002). Classification of sensitivity or resistance of cervical cancers to ionizing radiation according to expression profiles of 62 genes selected by cDNA microarray analysis. Neoplasia 4: 295–303. · DOI
- Maity SN, Sinha S, Ruteshouser EC, de Crombrugghe B . (1992). Three different polypeptides are necessary for DNA binding of the mammalian heteromeric CCAAT binding factor. J Biol Chem 267: 16574–16580. · DOI
- Matsuda K, Yoshida K, Taya Y, Nakamura K, Nakamura Y, Arakawa H . (2002). p53AIP1 regulates the mitochondrial apoptotic pathway. Cancer Res 62: 2883–2889.
- Mondal G, Sengupta S, Panda CK, Gollin SM, Saunders WS, Roychoudhury S . (2007). Overexpression of Cdc20 leads to impairment of the spindle assembly checkpoint and aneuploidization in oral cancer. Carcinogenesis 28: 81–92. · DOI
- Nagayama S, Katagiri T, Tsunoda T, Hosaka T, Nakashima Y, Araki N et al. (2002). Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res 62: 5859–5866.
- Nakamura T, Furukawa Y, Nakagawa H, Tsunoda T, Ohigashi H, Murata K et al. (2004). Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene 23: 2385–2400. · DOI · Paper page
- Nakamura Y . (2004). Isolation of p53-target genes and their functional analysis. Cancer Sci 95: 7–11. · DOI · Paper page
- Nishidate T, Katagiri T, Lin ML, Mano Y, Miki Y, Kasumi F et al. (2004). Genome-wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis. Int J Oncol 25: 797–819.
- Obama K, Ura K, Li M, Katagiri T, Tsunoda T, Nomura A et al. (2005). Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma. Hepatology 41: 1339–1348. · DOI
- Ochi K, Daigo Y, Katagiri T, Nagayama S, Tsunoda T, Myoui A et al. (2004). Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. Int J Oncol 24: 647–655.
- Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T et al. (2000). p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102: 849–862. · DOI · Paper page
- Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y et al. (2001). Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 61: 2129–2137.
- Okada K, Katagiri T, Tsunoda T, Mizutani Y, Suzuki Y, Kamada M et al. (2003). Analysis of gene-expression profiles in testicular seminomas using a genome-wide cDNA microarray. Int J Oncol 23: 1615–1635.
- Okutsu J, Tsunoda T, Kaneta Y, Katagiri T, Kitahara O, Zembutsu H et al. (2002). Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis. Mol Cancer Ther 1: 1035–1042.
- Ono K, Tanaka T, Tsunoda T, Kitahara O, Kihara C, Okamoto A et al. (2000). Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 60: 5007–5011.
- Roth JA . (2006). Adenovirus p53 gene therapy. Expert Opin Biol Ther 6: 55–61. · DOI · Paper page
- Seto E, Usheva A, Zambetti GP, Momand J, Horikoshi N, Weinmann R et al. (1992). Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci USA 89: 12028–12032. · DOI · Paper page
- Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712. · DOI · Paper page
- Soussi T, Asselain B, Hamroun D, Kato S, Ishioka C, Claustres M et al. (2006). Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection. Clin Cancer Res 12: 62–69. · DOI · Paper page
- St Clair S, Giono L, Varmeh-Ziaie S, Resnick-Silverman L, Liu WJ, Padi A et al. (2004). DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. Mol Cell 16: 725–736. · DOI · Paper page
- Sun Y . (2006). p53 and its downstream proteins as molecular targets of cancer. Mol Carcinog 45: 409–415. · DOI
- Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T et al. (2005). Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 11: 2625–2636. · DOI · Paper page
- Tanikawa C, Matsuda K, Fukuda S, Nakamura Y, Arakawa H . (2003). p53RDL1 regulates p53-dependent apoptosis. Nat Cell Biol 5: 216–223. · DOI · Paper page
- Taniwaki M, Daigo Y, Ishikawa N, Takano A, Tsunoda T, Yasui W et al. (2006). Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. Int J Oncol 29: 567–575.
- Yamabuki T, Daigo Y, Kato T, Hayama S, Tsunoda T, Miyamoto M et al. (2006). Genome-wide gene expression profile analysis of esophageal squamous cell carcinomas. Int J Oncol 28: 1375–1384.
- Zaffaroni N, Pennati M, Daidone MG . (2005). Survivin as a target for new anticancer interventions. J Cell Mol Med 9: 360–372. · DOI · Paper page
- Zhou M, Yeager AM, Smith SD, Findley HW . (1995). Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood 85: 1608–1614. · DOI · Paper page
- Zwicker J, Lucibello FC, Wolfraim LA, Gross C, Truss M, Engeland K et al. (1995). Cell cycle regulation of the cyclin A, cdc25C and cdc2 genes is based on a common mechanism of transcriptional repression. EMBO J 14: 4514–4522. · DOI · Paper page
Cited by
Census and evaluation of p53 target genes
Fischer, M. (2017) · Oncogene · doi:10.1038/onc.2016.502 · Cited by 971
Ubiquitin–proteasome system (UPS) as a target for anticancer treatment
Park, J., Cho, J., & Song, E. J. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01281-8 · Cited by 408
p53 isoforms Δ133p53 and p53β are endogenous regulators of replicative cellular senescence
Fujita, K., Mondal, A. M., Horikawa, I., Nguyen, G. H., Kumamoto, K., Sohn, J. J., Bowman, E. D., Mathe, E. A., Schetter, A. J., Pine, S. R., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1928 · Cited by 336
WD40 repeat domain proteins: a novel target class?
Schapira, M., Tyers, M., Torrent, M., & Arrowsmith, C. H. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.179 · Cited by 335
Regulation of APC/C Activators in Mitosis and Meiosis
Pesin, J. A., & Orr-Weaver, T. L. (2008) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.041408.115949 · Cited by 321
Metadata
- Authors
- Kidokoro, T., Tanikawa, C., Furukawa, Y., Katagiri, T., Nakamura, Y., & Matsuda, K.
- Venue
- Oncogene
- Published
- 2007-09-17
- Volume
- 27
- Issue
- 11
- Pages
- 1562-1571
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1981401255
- Cited by
- 207
- References
- 7
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.